Efficacy of neoadjuvant bicalutamide and dutasteride as a cytoreductive regimen before prostate brachytherapy

Urology

Volumn 68, Issue 1, 2006, Pages 116-120

  Merrick, Gregory S ^a   Butler, Wayne M ^a   Wallner, Kent E ^b   Galbreath, Robert W ^a,c   Allen, Zachariah A ^b   Kurko, Brian ^a  

^a WHEELING JESUIT UNIVERSITY   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c Ohio University Eastern   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BICALUTAMIDE; DUTASTERIDE;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ARTICLE; BRACHYTHERAPY; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CANCER SIZE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; FOLLOW UP; HEIGHT; HUMAN; MALE; MULTIVARIATE ANALYSIS; ORGAN SIZE; PREDICTION; PRIORITY JOURNAL; PROSTATE CANCER; TRANSRECTAL ULTRASONOGRAPHY; TREATMENT OUTCOME;

AGED; ANDROGEN ANTAGONISTS; ANILIDES; ANTINEOPLASTIC AGENTS, HORMONAL; AZASTEROIDS; BRACHYTHERAPY; ENZYME INHIBITORS; HUMANS; MALE; NEOADJUVANT THERAPY; PROSTATE; PROSTATIC NEOPLASMS; TESTOSTERONE 5-ALPHA-REDUCTASE;

EID: 33745815334     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2006.01.061     Document Type: Article

References (25)

1. Merrick G.S., Wallner K.E., and Butler W.M. Permanent interstitial brachytherapy for the management of carcinoma of the prostate gland. J Urol 169 (2003) 1643-1652
2. Nag S., Beyer D., Friedland J., et al. American Brachytherapy Society recommendations for transperineal permanent brachytherapy of prostate cancer. Int J Radiat Oncol Biol Phys 44 (1999) 789-799
3. Lee W.R. The role of androgen deprivation therapy combined with prostate brachytherapy. Urology 60 suppl 3a (2002) 39-44
4. Merrick G.S. The shrinking role of hormonal therapy in prostate brachytherapy. counterpoint. Brachytherapy 2 (2003) 2-4
5. Pinault S., Tetu B., Gagnon J., et al. Transrectal ultrasound evaluation of local prostate cancer in patients treated with LHRH agonist and in combination with flutamide. Urology 39 (1992) 254-261
6. Whittington R., Broderick G., Arger P., et al. The effect of androgen deprivation on the early changes in prostate volume following transperineal ultrasound guided interstitial therapy for localized carcinoma of the prostate. Int J Radiat Oncol Biol Phys 44 (1999) 1107-1110
7. Frazier A., Kaufman N., Rosemburg S., et al. Prostate volume reduction induced by neoadjuvant androgen ablation in preparation for permanent radioactive seed implantation. (abstract). Radiother Oncol 55 suppl 1 (2000) 77
8. Blasko J., Ragde H., Grimm P., et al. Potential for neoadjuvant hormonal therapy with brachytherapy for prostate cancer. Mol Urol 1 (1997) 207-214
9. Kucway R., Vicini F., Huang R., et al. Prostate volume reduction with androgen deprivation therapy before interstitial brachytherapy. J Urol 167 (2002) 2443-2447
10. Hinerman-Mulroy A., Merrick G.S., Butler W.M., et al. Androgen deprivation-induced changes in prostate anatomy predict urinary morbidity following permanent interstitial brachytherapy. Int J Radiat Oncol Biol Phys 59 (2004) 1367-1382
11. Zelefsky M.J., Leibel S.A., Burman C.M., et al. Neoadjuvant hormonal therapy improves the therapeutic ratio in patients with bulky prostatic cancer treated with three-dimensional conformal radiation therapy. Int J Radiat Oncol Biol Phys 29 (1994) 755-761
12. Blank K.R., Whittington R., Arjomandy B., et al. Neoadjuvant androgen deprivation prior to transperineal prostate brachytherapy. smaller volumes, less morbidity. Cancer J Sci Am 5 (1999) 370-373
13. Solhjem M.C., Davis B.J., Pisansky T.M., et al. Prostate volume before and after permanent prostate brachytherapy in patients receiving neoadjuvant androgen suppression. Cancer J 10 (2004) 343-348
14. Sanghani M.V., Schultz D., Tempany C.M., et al. Quantifying the change in endorectal magnetic resonance imaging-defined tumor volume during neoadjuvant androgen suppression therapy in patients with prostate cancer. Urology 62 (2003) 487-491
15. Gleave M.E., Goldenberg S.L., Chin J.L., et al. Randomized comparative study of 3 versus 8-month neoadjuvant hormonal therapy before radical prostatectomy. biochemical and pathological effects. J Urol 166 (2001) 500-507
16. Henderson A., Langley S.E.M., and Laing R.W. Is bicalutamide equivalent to goserelin for prostate volume reduction before radiation therapy? A prospective, observational study. Clin Oncol 15 (2003) 318-321
17. Holzbeierlein J.M., McLaughlin M.D., and Thrasher J.B. Complications of androgen deprivation therapy for prostate cancer. Curr Opin Urol 14 (2004) 177-183
18. Smith M.R., Lee W.C., Brandman J., et al. Gonadotropin-releasing hormone agonists and fracture risk. a claims-based cohort study of men with nonmetastatic prostate cancer. J Clin Oncol 23 (2005) 7897-7903
19. Roehrborn C.G., Marks L.S., Fenter T., et al. Efficacy and safety of dutasteride in the four-year treatment of men with benign prostatic hyperplasia. Urology 63 (2004) 709-715
20. Miller N.L., Bissonette E.A., Bahnson R., et al. Impact of a novel neoadjuvant and adjuvant hormone-deprivation approach on quality of life, voiding function, and sexual function after prostate brachytherapy. Cancer 97 (2003) 1203-1210
21. Yoshimura K., Sumiyoshi Y., Hashimura T., et al. Neoadjuvant flutamide monotherapy for locally confined prostate cancer. Int J Urol 10 (2003) 190-195
22. Eri L.M., and Tveter K.J. A prospective, placebo-controlled study of the antiandrogen Casodex as treatment for patients with benign prostatic hyperplasia. J Urol 150 (1993) 90-94
23. Debruyne F., Barkin J., van Erps P., et al. Efficacy and safety of long-term treatment with the dual 5α-reductase inhibitor dutasteride in men with symptomatic benign prostatic hyperplasia. Eur Urol 46 (2004) 488-495
24. Iczkowski K.A., Qiu J., Qian J., et al. The dual 5-alpha-reductase inhibitor dutasteride induces atrophic changes and decreases relative cancer volume in human prostate. Urology 65 (2005) 76-82
25. Nishiyama T., Tomita Y., and Takahashi K. Influence of androgen deprivation therapy on volume of anatomic zones of prostate in patients with prostate cancer using magnetic resonance imaging. Urology 63 (2004) 917-921